This segment focuses on the development, commercialization, and ongoing research related to the PreTRM test, a blood-based biomarker test designed to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. Research and development activities include biomarker discovery, assay development, clinical validation through trials like the PRIME study, and continuous improvement of the test's accuracy and performance. The PreTRM test utilizes advanced proteomic and analytical technologies to measure specific proteins in a pregnant woman's blood. This segment addresses the critical need for early identification of women at risk of preterm birth, enabling timely interventions and improved patient outcomes. Market positioning is centered on providing a valuable tool for obstetricians and maternal-fetal medicine specialists. Future opportunities include expanding the test's applications, such as predicting other pregnancy complications, and further clinical validation to support broader adoption. Regulatory aspects involve FDA approval and adherence to clinical guidelines. Partnerships with healthcare providers and insurance companies are crucial for market access and reimbursement.